Skepticism over clinical trial design sank Medtronic PLC’s DIAM Spinal Stabilization System at a Feb. 19 meeting of the FDA Orthopaedic and Rehabilitation Devices Panel. The majority of the 11-member panel found that the evidence did not show that the device was safe or effective, or that its benefits outweighed its risks.
The DIAM, which has been CE marked in Europe for more than a decade, is used to treat moderate degenerative disc disease in adults. Seven of the 11 panelists voted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?